These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15644444)

  • 1. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
    Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 is a direct transcriptional target of MYCN in neuroblastoma.
    Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
    Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.
    Gu L; Zhang H; He J; Li J; Huang M; Zhou M
    Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
    Evans L; Chen L; Milazzo G; Gherardi S; Perini G; Willmore E; Newell DR; Tweddle DA
    Cancer Lett; 2015 Jul; 363(1):37-45. PubMed ID: 25843293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
    Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
    Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.
    Slack A; Shohet JM
    Cell Cycle; 2005 Jul; 4(7):857-60. PubMed ID: 15917661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
    Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
    Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
    Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
    Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
    Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive auto-regulation of MYCN in human neuroblastoma.
    Suenaga Y; Kaneko Y; Matsumoto D; Hossain MS; Ozaki T; Nakagawara A
    Biochem Biophys Res Commun; 2009 Dec; 390(1):21-6. PubMed ID: 19766596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.